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Abstract
It is well established that tau pathology propagates in a predictable manner in Alzheimer’s disease (AD). Moreover, tau
accumulates in the cerebrospinal fluid (CSF) of AD’s patients. The mechanisms underlying the propagation of tau pathology
and its accumulation in the CSF remain to be elucidated. Recent studies have reported that human tau was secreted by
neurons and non-neuronal cells when it was overexpressed indicating that tau secretion could contribute to the spreading
of tau pathology in the brain and could lead to its accumulation in the CSF. In the present study, we showed that the
overexpression of human tau resulted in its secretion by Hela cells. The main form of tau secreted by these cells was cleaved
at the C-terminal. Surprisingly, secreted tau was dephosphorylated at several sites in comparison to intracellular tau which
presented a strong immunoreactivity to all phospho-dependent antibodies tested. Our data also revealed that
phosphorylation and cleavage of tau favored its secretion by Hela cells. Indeed, the mimicking of phosphorylation at 12
sites known to be phosphorylated in AD enhanced tau secretion. A mutant form of tau truncated at D421, the preferential
cleavage site of caspase-3, was also significantly more secreted than wild-type tau. Taken together, our results indicate that
hyperphosphorylation and cleavage of tau by favoring its secretion could contribute to the propagation of tau pathology in
the brain and its accumulation in the CSF.
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Introduction
The microtubule-associated protein tau that is normally
enriched in the axon becomes hyperphosphorylated and accumu-
lates in the somato-dendritic compartment in several neurode-
generative diseases named tauopathies that are characterized by
dementia [1,2]. In these diseases that include AD, tau aggregates
in insoluble filaments that form lesions called neurofibrillary
tangles (NFTs) [3]. The appearence of these lesions in a
predictable manner in the brain correlates with the degree of
cognitive deficits [4,5,6,7]. Moreover, the amount of tau found in
CSF increases during progression of AD [8]. It remains unclear
how tau pathology propagates in the brain and how tau reaches
the CSF. Recent studies have reported that the secretion of tau
could contribute to both of these events. In vitro, tau was shown to
be secreted by M1C, NB2a/d1, COS-7 and KEK-293 cells
[9,10,11]. When human tau cDNA was microinjected in central
lamprey neurons, human tau could transfer from one neuron to
another indicating that secreted tau could be involved in the
propagation of the disease in vivo [10]. However, it was unclear
whether this phenomenon was specific to this model until two
recent studies demonstrating the trans-synaptic propagation of tau
pathology in a mouse model [12,13]. In this model, where human
tau overexpression was restricted in the entorhinal cortex, the first
region to be affected in AD, the spreading of tau pathology was
observed along synaptically connected circuits. From these studies,
one can conclude that the secretion of tau at the synapse might be
involved in the propagation of tau pathology in mouse brain. Tau
secretion could also result in the increase of tau in the CSF as
reported in a study showing that the increased amount of tau in
the CSF could not be linked to neurodegeneration in tau
transgenic mouse models [14].
In AD, tau is phosphorylated at more than 40 sites compared to
9 sites in normal patients [15]. Until now, only few phosphory-
lation sites were examined in CSF. In several studies, both the
amount of total tau and phosphorylated tau (ptau) were measured
in the CSF [8]. Indeed, the ratio of ptau/total tau was shown to be
more accurate in distinguishing Alzheimer’s patients from controls
than the mere measure of total tau. The phosphorylation of
threonine 181 (T181) is extensively used for measuring tau in the
CSF [8]. In AD and in mildly cognitive impaired patients, the
phosphorylation of T181 is significantly higher than in normal
patients whereas it is decreased in patients presenting a fronto-
temporal dementia (FTD) [16,17]. Moreover, phopshorylation of
T181 was used to differentiate AD from dementia with Lewy
bodies (DLB) [18]. The phosphorylation of T231 was also
increased in CSF tau obtained from AD patients
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phosphorylation of T231 decreased with the progression of AD
[24]. The phosphorylation of T231 is lower in FTD than in AD
[18]. The above observations revealed that the distinct pattern of
tau phosphorylation could be used to discriminate between
tauopathies. The phosphorylation of other sites such as S199,
S202 and T205 (epitope recognized by the phospho-tau antibody
AT8) and S396 and S404 (epitope recognized by the phospho-tau
antibody PHF-1) were less examined and their phosphorylation in
CSF remains controversial [25]. The low amount of tau in the
CSF has been a limiting factor in characterizing its phosphory-
lation state. So far, the increase of tau in the CSF was attributed to
neuronal cell death. A recent study reported that intracellular tau
released in the culture medium upon cell death was dephosphor-
ylated [26]. It remains to be determined whether tau found in the
CSF has a phosphorylation pattern similar to that of intraneuronal
tau.
Tau found in the CSF of AD and progressive supranuclear palsy
(PSP) patients is cleaved [27,28,29]. The main cleavage seems to
occur at the C-terminal. It is still unclear whether tau is cleaved
before it is released in the CSF. A study reported that when full-
length tau was added to the CSF, it did not get cleaved indicating
that the cleavage of tau took place before its release in the CSF
[27]. Interestingly, CSF-tau obtained from tau transgenic mice
was also cleaved at the C-terminal [14]. A recent study reported
that tau secreted by M1C and NB2a/d1 cell lines was cleaved at
the C-terminal in a pattern reminiscent to tau found in the CSF
[9,30]. All together, the above observations revealed that tau
cleaved at the C-terminal is preferentially released in the CSF.
Until now, no study has examined whether phosphorylation and
cleavage of tau favor its secretion. In the present study, we showed
that the overexpression of human tau resulted in its secretion by
Hela cells. Interestingly, secreted tau was dephosphorylated at
several sites in comparison to intracellular tau and that only tau
cleaved at the C-terminal was found in the medium. Our data also
revealed that hyperphosphorylation and cleavage of tau favored its
secretion by Hela cells. Therefore, hyperphosphorylation and
cleavage enhancing the secretion of tau in AD brain could
contribute to the propagation of its pathology in the brain and to
its accumulation in the CSF. From the present results showing that
secreted tau was dephosphorylated and the previous study
reporting that tau released in the culture medium upon cell death
was dephosphorylated, one can also speculate that tau found in the
CSF would be dephosphorylated.
Materials and Methods
Cell Culture and Transfection
Hela cells (ATCC, Manassas, VA, USA) were cultured in
DMEM (Invitrogen, Burlington, ON, Canada) supplemented with
10% foetal bovine serum (Hyclone, Logan, UT) and 2 mM L-
glutamine (Sigma, Oakville, ON, Canada) at 37uC in a humidified
5% CO2 incubator. For transfection, Hela cells were plated at a
density of 1.1 6 10
6 cells in 60-mm Petri dishes and grown
overnight to 80% confluency. Lipofectamine 2000 (Invitrogen) was
used to transfect Hela cells with the expression vector (pEGFP-C1
from Clonetech) containing either wild-type human 4R tau (wild-
type htau) or human 4R tau mutant fused at the C-terminus of a
Green Fluorescent Protein (GFP) tag or with the pRc/CMV
vector containing wild-type human tau fused at the C-terminus of
a Flag tag (kindly provided by Dr. Gloria Lee, University of Iowa,
Iowa, IA). Briefly, for each petri, 8 mg of plasmid DNA was mixed
with 500 ml of Opti-MEM medium (Invitrogen), and 16 mlo f
Lipofectamine 2000 was mixed with 500 ml of Opti-MEM
medium. Both mixtures were incubated for 5 min then mixed
and left standing for 20 min. Then, 1 ml of the mixture was added
to each petri. After an incubation of 4 hrs at 37uC, culture
medium was replaced by 6 ml of fresh medium. The GFP-4Rtau
construct was kindly provided by Dr. Ken Kosik (University of
California, Santa Barbara, CA, USA; Lu and Kosik 2001), human
4R tau mutants, A12 and E12, containing 12 phosphorylation sites
(S199, S202, T205, S214, T231, S235, S262, S356, S396, S400,
S404 and S409) mutated in alanine and glutamate respectively,
were modified from the GFP-4Rtau construct in our laboratory
and tauD413–441 and tauD422–441 were generated from GFP-
4Rtau construct by Mutagenex (Piscataway, NJ, USA). Two days
after transfection or as mentioned in the text, culture medium was
harvested and cells were lysed for immunoblotting.
Preparation of Cell Lysate and Culture Medium
Containing Tau
Two days after transfection, the culture medium was collected
and centrifuged at 3000 RPM for 10 min at room temperature to
remove cell debris. After the culture medium was collected, the
cells were immediately washed twice with phosphate buffered
saline (PBS) and once with PBS containing 0.5 M NaCl to detach
proteins non-specifically attached at the cell surface [31]. The cells
were then lysed in 6 ml of fresh culture medium supplemented
with 0.1% Triton X-100 and protease inhibitor cocktail 1X
(Complete EDTA-free from Roche Diagnostics, Indianapolis, IN,
USA) and then incubated on ice for 10 min. The cell lysate was
vortexed and then centrifugated at 3000 RPM for 10 min at room
temperature.
Isolation of Microvesicles/exosomes
Two days after transfection, the culture medium was collected.
The isolation of microvesicles/exosomes was performed using
differential centrifugation as described by Thery et al. [32]. Briefly,
the culture medium was centrifuged at 300xg for 10 min, then at
2000xg for 10 min and at 10,000xg for 30 min at 4uC to remove
cell debris. The microvesicles/exosomes were isolated by a
centrifugation at 100,000xg for 120 min at 4uC. Microvesicles/
exosomes were washed in PBS and centrifuged again at 100,000xg
for 60 min at 4uC. The presence of tau in the pellet containing the
microvesicles/exosomes was analyzed by western blotting.
Immunoprecipitation
To analyze the phosphorylation pattern of secreted tau, tau
was immunoprecipitated from the culture medium and the cell
lysate. Magnetic beads coupled with anti-mouse antibodies
(DYNAL Biotech, DynabeadsH M-280 Sheep anti-Mouse IgG)
were washed in PBS and incubated O/N at 4uC with the
following antibodies: 0.3 mg Tau-1, 0.1 mg HT7 and 6 ml CP13
(kindly provided by Dr. Peter Davies, Albert Einstein University,
Bronx, NY, USA). The beads were then washed and incubated
for 2 hrs at 4uC with 1.5 ml of the culture medium or the cell
lysate. The complex bead-antibody-antigen was then washed,
resuspended in 80 ml of sample buffer 1X and boiled for 5 min.
Then, 40 ml of the samples were loaded per well and separated
on 7.5% polyacrylamide gel. Immunoblotting was performed as
described below.
Immunoblotting
Equal amount of the culture medium and the cell lysate (20
or 40 ml) were loaded in each lane and electrophoresed on a
7.5% polyacrylamide gel. Following separation, proteins were
electrophoretically transferred to a nitrocellulose membrane.
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antibodies O/N at 4uC. They were then washed with Tris-
buffered saline with 0.2% Tween-20 (Sigma) and incubated with
the peroxidase-conjugated secondary antibodies (Jackson Im-
munoresearch Laboratories, Missisauga, ON, Canada). Mem-
branes were again washed and revealed by chemiluminescence
(Amersham Pharmacia Biotech, Quebec, Quebec, Canada).
Many tau antibodies were used to visualize either the
phosphorylation state or different epitopes of the protein (see
Table 1). We also used a mouse monoclonal anti-tubulin
(1:2000) (clone DM1A from Sigma) to assess the cell death and
a mouse monoclonal anti-GFP antibody (mix of clones 7.1 and
13.1) (1:5000) (Roche Diagnostics).
Treatment with Brefeldin A, Caspase-3 Inhibitor and Low
Temperature Assays
Two days after transfection, the culture medium was changed
for fresh medium and the cells were treated for 4:30 hrs with
brefeldin A (BFA) (Sigma) at a concentration of 5 mg/ml, diluted
in 0.05% of dimethyl sulfoxide (DMSO) (Sigma). Control cells
were treated with 0.05% DMSO. Cells were also treated with the
caspase-3 inhibitor Z-DEVD-FMK (TOCRIS, Minneapolis, MN,
USA). Twenty-four hrs after transfection, the culture medium was
changed for fresh medium and the cells were treated with 20 mM
of the caspase-3 inhibitor or 20 mM of DMSO for 24 hrs.
Alternatively, cells were subjected to changes in temperature.
To do so, cells were plated in 25 cm
2 flasks instead of 60-mm
petri dishes. The transfection was performed as described above.
Two days after transfection, culture medium was changed for
fresh medium and the cells were incubated at 18 or 4uC for
6 hrs. Control cells were incubated at 37uC. The cell lysate and
the culture medium containing tau were prepared as described
above.
Quantification of Cell Death
Cell death was assessed by the measurement of the LDH activity
in the culture medium and the cell lysate using the LDH
cytotoxicity assay kit from Cayman Chemical Company (Ann
Arbor, MI, USA), according to the manufacturer’s instructions.
The cell death percentage was evaluated by the LDH activity in
the culture medium (M) and the cell lysate (L) using the following
formula: LDH Activity in M/total LDH Activity (Activity in M +
L). Triplicates were performed for each sample. The LDH content
in the samples was measured with a BIO-TEK Elx800 plate
reader. The percentages of cell death are presented as the mean 6
standard error of the mean (SEM).
Cell death was also evaluated by trypan blue exclusion
method. Briefly, Hela cells were cultured on glass coverslip.
Two days after transfection, cells were washed twice with PBS
and then incubated in 0.2% trypan blue (Sigma) diluted in PBS
for 4 min at room temperature (RT). Cells were then washed
once with PBS and fixed in 4% paraformaldehyde in PBS for
5 min at 4uC and 10 min at RT. Cultures were kept in PBS
until they were observed by light microscopy. The number of
blue cells (dead cells) and total cells were counted on ten
different fields and the cell death percentage was evaluated by
the ratio of blue cells on total cells.
Table 1. List of tau antibodies.
Antibody Type Epitope WB dilution Source
HT7 Mouse monoclonal between a.a. 159–163 1:500 Pierce Biotechnology, Rockford, IL, USA
K9JA Rabbit polyclonal a.a. 243–441 1:20 000 DakoCytomation, Glostrup, Denmark
Tau1 Mouse monoclonal dephosphorylated a.a. 195, 198, 199 and 202 n/a Millipore, Billerica, MA, USA
Tau12 Mouse monoclonal Between a.a. 9–18 1:5000–1:20 000 Abcam, Cambridge, MA, USA
Tau46 Mouse monoclonal a.a. 428–441 1:500 Abcam, Cambridge, MA, USA
AT270 Mouse monoclonal pT181 1:100 Pierce Biotechnology, Rockford, IL, USA
Phospho-S199 Rabbit polyclonal pS199 1:1000 Biosource-Invitrogen, Burlington, ON,
Canada
CP13 Mouse monoclonal pS202 1:50 Kindly provided by Dr. Peter Davies, Albert
Einstein College of Medicine, NY, USA
Phospho-T205 Rabbit polyclonal pT205 1:500 Biosource-Invitrogen, Burlington, ON,
Canada
Phospho-T212 Rabbit polyclonal pT212 1:1000 Biosource-Invitrogen, Burlington, ON,
Canada
Phospho-S214 Rabbit polyclonal pS214 1:100 Biosource-Invitrogen, Burlington, ON,
Canada
Phospho-T217 Rabbit polyclonal pT217 1:1000 Biosource-Invitrogen, Burlington, ON,
Canada
Phospho-S262 Rabbit polyclonal pS262 1:1000 Signalway antibody, Pearland, TX, USA
Phospho-S409 Rabbit polyclonal pS409 1:100 Biosource-Invitrogen, Burlington, ON,
Canada
Phospho-S422 Rabbit polyclonal pS422 1:1000 Biosource-Invitrogen, Burlington, ON,
Canada
AT180 Mouse monoclonal pT231/pS235 1:100 Pierce Biotechnology, Rockford, IL, USA
PHF-1 Mouse monoclonal pS396/pS404 1:100 Kindly provided by Dr. Peter Davies, Albert
Einstein College of Medicine, NY, USA
doi:10.1371/journal.pone.0036873.t001
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Antibodies by Densitometry
Films were scanned with an EPSON PERFECTION 1240U
scanner and transparency module EPSON EU-33, using Adobe
Photoshop version 7.0 software. Image J software version 1.38X
from the National Institute of Health was used to quantify the
intensity of the band obtained with the different antibodies in the
culture medium and the cell lysate prepared from Hela cells
overexpressing either wild-type tau or mutated tau. To compare
the secretion levels of wild-type tau with that of tau mutants, A12,
E12, tauD413–441 and tauD422–441, the immunoblots were
stained with the anti-tau antibody Tau12 that recognizes
phosphorylated and non-phosphorylated tau and then the
intensity of bands was measured by densitometry to calculate the
ratio of the signal in the culture medium and the cell lysate. To
compare the secretion levels of wild-type tau with or without the
caspase-3 inhibitor, the immunoblots were stained with the anti-
tau antibody Tau12 and then the intensity of bands was measured
by densitometry to calculate the ratio of the signal in the culture
medium and the cell lysate.
Statistical Analysis
Statistical significance was evaluated with a one-way analysis of
variance (ANOVA) followed by Dunnett multiple comparisons test
against tau mutant E12 for the set of experiments on the effects of
phosphorylation on tau secretion and against wild-type tau for the
set of experiments on the effects of the C-terminal cleavage on tau
secretion. The effect of caspase-3 inhibition on tau secretion was
analyzed by a Paired t test. The statistical analysis was performed
using the GraphPad InStat 3 software and p,0.05 was considered
significant.
Results
Human Tau is Secreted by Hela Cells
Human tau fused to the GFP tag (GFP-tau) was overexpressed
in Hela cells. In the cell lysate at 48 hrs after transfection, a tau-
postive band revealed by the anti-tau antibody Tau12 was found
just above 75 kDa as expected when tau is fused to GFP
(Figure 1A). A Tau12- positive band at 75 kDa as well as lower
molecular weight bands between 37 and 50 kDa and 25 and
37 kDa were consistently observed but at a significantly lower
intensity than the band of full-length tau indicating that
overexpressed human tau was cleaved in Hela cells. A similar
pattern of tau-positive bands was observed with the anti-tau
antibody, HT7, and a polyclonal anti-tau antibody (poly anti-
tau). No tau-positive band was detected with the anti-tau
antibodies Tau12 and HT7 but three non-specific bands were
detected with the polyclonal anti-tau antibody when cell lysates
were prepared from Hela cells transfected with the empty GFP
vector (Figure 1A). Surprisingly, the tau-positive band found at
75 kDa in the cell lysate was also present in the culture medium
and became more abundant with time as noted at 24, 41 and
51 hrs after transfection (Figure 1B). However, full-length tau
was consistently absent from the culture medium. Tau-positive
bands were also noted between 37 and 50 kDa and 25 and
37 kDa in the culture medium as observed in the cell lysate. The
fact that tau-positive bands detected in the medium were also
noted in the cell lysate could indicate that some extracellular tau
remained attached to the cells after washing them before lysis.
To verify this possibility, cells were washed with PBS containing
0.5 M NaCl, a solution used to remove non-specific binding of
proteins at the surface of cultured cells [31]. Under this washing
condition, the tau-positive band at 75 kDa was still present in the
cell lysate indicating that it could correspond to an intracellular
pool of cleaved tau.
We next examined whether tau found in the medium was
released by Hela cells either through cell death or secretion. To
demonstrate that the presence of tau in the culture medium was
not caused by membrane leakage from dying cells but rather by
an active process of secretion, three approaches were used. First,
the presence of a cytosolic protein such as tubulin in the culture
medium from control and cells overexpressing tau was analyzed
(Figure 2A). No tubulin was noted in the culture medium before
and after overexpression of human tau consistent with the fact
that no cell lysis was induced by the overexpression of human
Figure 1. Overexpressed human tau in Hela cells is found in the
culture medium. (A) In the cell lysate (L) prepared from Hela cells
overexpressing human tau fused to the GFP tag, a tau- positive band
just above 75 kDa and a band at 75 kDa corresponding to full-length
and cleaved tau, respectively, were observed with the anti-tau
antibodies Tau12, HT7 and a polyclonal antibody (arrows). No signal
was detected with the anti-tau antibodies in L prepared from Hela cells
transfected with the empty GFP-vector except for three non-specific
bands detected with the polyclonal anti-tau antibody. Tau-positive
bands migrating between 37 and 50 kDa and 25 and 37 kDa were also
observed with the anti-tau antibodies. (B) The tau-positive band found
at 75 kDa in L was also detected in the culture medium (M) and it
increased with time as noted at 24, 41 and 51 hrs after transfection. No
tau-positive bands were noted in M collected from cells transfected
with the empty GFP vector except one non-specific band at ,50 kDa
detected with the polyclonal anti-tau antibody.
doi:10.1371/journal.pone.0036873.g001
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prepared in 6 ml of lysis buffer for comparison with the 6 ml of
medium used to maintain Hela cells after transfection, tubulin
staining was detected (Figure 2A). To further confirm that the
presence of tau in the medium was caused by its secretion and
not cell lysis, Hela cells overexpressing tau were partially lysed
for few seconds in a solution of 0.01% Triton X-100 to induce
some damage at the plasma membrane. In this condition,
tubulin and full-length tau were detected in the medium
confirming that full-length tau and tubulin would be found in
the culture medium if Hela cells had been damaged by tau
overexpression (Figure 2A and B). Second, cell death was
evaluated by the trypan blue exclusion method and by the
lactate dehydrogenase (LDH) activity measurement in the
medium (Figure 2C) [33,34]. From the trypan blue staining, it
was possible to conclude that the presence of tau in the medium
was not caused by cell death since an important amount of tau
was found in the medium even when cell death was evaluated
to be less than 1%. The LDH activity in the culture medium
was measured for each set of experiments and allowed us to
determine that the cell death percentage of Hela cells
overexpressing tau varied from 0% to 5% in most experiments.
From the trypan blue staining and LDH activity, no correlation
could be established between the percentage of cell death and
the amount of tau in the medium confirming the secretion of
tau by Hela cells. Third, to demonstrate that tau was secreted
by an active process by Hela cells, the secretion of tau was
examined when the cells were incubated at low temperature, a
condition known to decrease secretion by exocytosis [34,35].
The amount of tau in the medium was significantly reduced at
low temperature although no difference was noted between
18uC and 4uC (Figure 3A). The percentage of cell death was
0.3560.35, 3.261.1 and 2.6461.87 at 37uC, 18uC and 4uC
respectively. To eliminate the possibility that the GFP tag which
can be secreted when misfolded could contribute to tau
secretion, the secretion of human tau fused to a Flag tag was
examined in Hela cells [36]. As noted for GFP-tau, Flag-tau
was found in the medium and its secretion was also impaired at
low temperature (Figure 3B). The percentage of cell death was
0, 3.6760.30 and 3.3260.54 at 37uC, 18uC and 4uC
respectively. For both GFP-tau and Flag-tau, an increase of
cell death was noted at low temperature whereas tau secretion
was decreased showing that the presence of tau in the culture
medium was not imputable to cell lysis.
We next examined whether tau was secreted through the
conventional pathway by treating the cells with brefeldin A (BFA),
a drug known to inhibit this secretory pathway [37]. BFA did not
prevent the secretion of GFP-tau and Flag-tau by Hela cells
indicating that their secretion occurs through a non-conventional
pathway (percentage of cell death: 0% for control and BFA treated
cells)(Figure 3C and D).
In previous studies, it was shown that secreted tau was found in
microvesicles and exosomes [11,30]. We examined whether tau
secreted by Hela cells was included in vesicles. Medium containing
tau was centrifuged to isolate microvesicles/exosomes as described
by Thery et al. [32]. The presence of tau in the supernatant and
pellet was examined by western blotting. The amount of tau
present in the supernatant was similar to that found in the medium
that has not been centrifuged indicating that the major portion of
tau secreted by Hela cells was not included in microvesicles/
exosomes (Figure 3E). However, tau could be detected in the pellet
when it was resuspended in a small volume revealing that a small
pool of secreted tau was found in microvesicles/exosomes (data
not shown).
Human Tau Secreted by Hela Cells is Cleaved at the C-
terminal
Tau secreted in the culture medium was consistently cleaved.
Two observations pointed out that tau was most likely cleaved
before being secreted by Hela cells. First, the tau-positive band at
75 kDa as well as lower tau-positive bands present in the culture
medium were often observed in the cell lysate. Second, when
recombinant human tau protein was added to the culture medium
of control cells for 48 hrs, full-length tau was detectable although
some degradation had occurred (Figure 4A). This indicated that if
full-length tau was secreted by Hela cells, it should not have been
completely degraded in the culture medium after 48 hrs of
transfection.
A panoply of antibodies directed against different regions of
tau were employed to analyze the cleavage pattern of tau in the
culture medium and cell lysate (Table 1). In the cell lysate, all
antibodies tested could detect full-length tau (Figure 4B, C, D
and E). The band found at 75 kDa in both the cell lysate and
culture medium was also detected by all the antibodies tested
except for the antibody Tau46 that recognizes the peptidic
sequence located between L428 and L441 [38]. This indicated
that tau found at 75 kDa was cleaved at the C-terminal as
reported for tau present in the CSF of both humans and tau
transgenic mice and for tau secreted by M1C and NB2a/d1
cells [9,14,27,28,29,30].
The band located at 75 kDa mainly present in the medium was
immunoreactive to the antibody Tau12 directed against an
epitope (9–18 a.a.) located at the N-terminal of tau (Figure 4B).
This band was also detected by an anti-GFP antibody confirming
that no cleavage had occurred at the N-terminal of tau where the
GFP tag was inserted (Figure 4C). The antibody Tau12 could also
detect bands found between 37 and 50 kDa and bands between 25
and 37 kDa revealing that the N-terminal was contained in these
tau truncated forms (Figure 4B).
The antibody K9JA directed against an epitope located in the
microtubule-binding domain (MTBD) of tau revealed the band
found at 75 kDa and bands between 37 and 50 kDa and bands
between 25 and 37 kDa (Figure 4D). At around 37 kDa, a
strong signal was detected with the anti-tau antibody Tau12 and
the anti-GFP antibody whereas a weak signal was noted with
the K9JA antibody indicating that the MBTD could be cleaved
in these tau fragments. Finally, no band lower than 75 kDa was
detected with the antibody Tau46 directed against an epitope
located at the C-terminal. This implies that the lower tau
fragments were generated from cleaved tau found at 75 kDa
lacking the C-terminal in both the cell lysate and culture
medium (Figure 4E).
Distinct Phosphorylation Pattern of Intracellular and
Extracellular Tau
In the cell lysate, full-length tau was phosphorylated at several
sites known to be hyperphosphorylated in Alzheimer brain
including early (T181, AT8 and S262), intermediate (AT100
and AT180) and late sites (PHF-1 and S422) (Figure 5).
Surprisingly, several sites phosphorylated in intracellular tau were
either not phosphorylated or less importantly phosphorylated in
extracellular tau. The phosphorylation of two of the three sites
(S199, S202 and T205) forming the epitope of the antibody AT8,
S202 and T205, was not detectable in the medium although a
strong signal was observed in the cell lysate (Figure 5C and D). A
similar observation was made for the PHF-1 antibody recognizing
tau phosphorylated at S396 and S404 as well as for the antibody
pS422 directed against tau phosphorylated at S422 (Figure 5J and
Hyperphosphorylated and Cleaved Tau Is Secreted
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the epitope of the antibodies AT100 (T212/S214/T217) and
AT180 (T231/S235) as well as T181, S199, S262 and S409
(Figure 5A, B, E, F, G, H, I and K). For most phospho-tau
antibodies, a band was detected in the medium only after a long
film exposure which resulted in the saturation of the signal
observed in the cell lysate. This indicated that tau found in the
medium was less phosphorylated than intracellular tau. To
confirm this, the amount of total tau in the medium and cell
lysate was examined using the phospho-independent antibody
Tau12. As illustrated in Figure 5, the amount of total tau and
phospho-tau was similar in the cell lysate whereas in the medium,
the amount of total tau was significantly higher than that of
phospho-tau. The above results led us to conclude that extracel-
lular tau was significantly less phosphorylated than intracellular
tau.
Phosphorylation Favors the Secretion of Tau by Hela
Cells
The decreased phosphorylation of tau found at 75 kDa in the
culture medium could indicate that either dephosphorylation
favored the secretion of tau or dephosphorylation of tau occurred
during the process of secretion in Hela cells. To verify whether
dephosphorylation enhanced tau secretion, a tau mutant present-
ing mutations in alanine at 12 sites (A12) known to be
phosphorylated in Hela cells was generated and overexpressed in
these cells. Secreted A12 mutant was cleaved and was not more
secreted than wild-type tau indicating that dephosphorylation
would not be a determinant factor in tau secretion (Figure 6A). To
further investigate how phosphorylation modulated tau secretion
by Hela cells, we produced a mutant where the 12 above sites were
mutated in glutamate (E12) to mimic phosphorylation. Interest-
ingly, this mutant was more secreted than wild-type tau and A12
Figure 2. Overexpressed human tau is secreted by Hela cells. (A) No tubulin was noted in M before and after overexpression of human tau
whereas tubulin staining was detected in the cell lysate (Total lysis) prepared in 6 ml of lysis buffer for comparison with the 6 ml of medium used to
maintain Hela cells after transfection (arrow). In M collected from Hela cells overexpressing tau that were partially lysed (Partial Lysis) for few seconds
in a solution of 0.01% Triton X-100 to induce some damage at the plasma membrane, tubulin staining became detectable (asterisk). (B) Cleaved tau
was detected in M and L (lower arrow) whereas full-length tau was only detected in L (upper arrow in Total lysis). Full-length tau became detectable
in M when Hela cells were partially lysed (Partial lysis) with a solution of 0.01% Triton X-100 (upper arrow). (C) Hela cells overexpressing human tau
were stained with Trypan blue before being fixed to evaluate the percentage of cell death. Blue cells (arrow) corresponded to dead cells that had
taken up Trypan blue.
doi:10.1371/journal.pone.0036873.g002
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e36873Figure 3. Secretion of human tau is reduced at low temperature and is not prevented by BFA treatment. (A) The amount of GFP-tau in
M (lower arrow) was reduced at low temperature (18uC and 4uC) whereas the expression of tau was not affected (upper arrow). (B) Human tau fused
to a Flag tag was also secreted by Hela cells. Secreted Flag-tau was cleaved as noted for GFP-tau (upper and lower arrows). The secretion of Flag-tau
(lower arrow) but not its expression (upper arrow) was also impaired at low temperature. (C and D) The secretion of both GFP-tau and Flag-tau was
not affected by BFA. Control cells (Ctrl) were treated with DMSO, the vehicle of BFA. BFA treatment was tested at least in three sets of experiments. E)
The amount of wild-type tau in M was not decreased after ultracentrifugation to remove microvesicles/exosomes.
doi:10.1371/journal.pone.0036873.g003
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observed for wild-type tau and A12 mutant. To measure the
secretion of wild-type tau, A12 and E12 mutants, the signal of the
tau-positive band found at 75 kDa in the medium was quantified
by densitometry as well as the signal of the band corresponding to
full-length tau and that at 75 kDa present in the cell lysate. The
secretion of tau was evaluated by calculating the ratio of the signal
obtained with the anti-tau antibody Tau12 in the culture medium
(M) and cell lysate (L) (Ratio M/L). The mean of the ratio M/L
was 0.1660.03, 0.3760.070 and 0.1960.03 for wild-type tau, E12
Figure 4. Secreted tau is cleaved at the C-terminal. (A) Full-length recombinant human tau protein (rTau4R) was still detectable in the culture
medium after being added to control Hela cells for 48 hrs (arrow, M+cells). rTau4R was less degraded when it was added to M without cells (M) (B)
Secreted tau is not cleaved at the N-terminal as revealed by the anti-tau antibody Tau12 directed against the 9–18 a.a. A Tau12-positive band was
detected in both L and M prepared from Hela cells overexpressing GFP-tau4R corresponding to full-length and cleaved tau (upper and lower arrows).
(C) GFP tag inserted at the N-terminal of tau was detected in tau present in both L and M (upper and lower arrows). (D) The microtubule-binding
domain of tau was not cleaved in tau secreted by Hela cells as revealed by the K9JA antibody (lower arrow). (E) The band found at 75 kDa in both L
and M was not detected by the antibody Tau46 that recognizes the peptidic sequence located between L428 and L441. Only full-length tau present
in L was detected with this antibody (arrow). A non-specific band at ,100 kDa was noted with the antibody Tau46 in M. The pattern of each antibody
was analyzed at least in 3 sets of experiments.
doi:10.1371/journal.pone.0036873.g004
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significantly higher (,2 times) than that of wild-type tau and A12.
The percentage of cell death for wild-type tau, E12, A12 and was
4.961.59, 4.3361.95 and 2.5761.67 respectively. From the
above data, one could conclude that phosphorylation favored
the secretion of tau by Hela cells.
Tau Cleaved at D421 is Preferentially Secreted by Hela
Cells
Tau present in the culture medium was always cleaved. This
could signify that cleaved tau was preferentially targeted to the
secretory pathway. To verify this possibility, tau mutants cleaved
at the C-terminal were overexpressed in Hela cells. In the
previous section (Figure 5), the staining of secreted tau with
different phospho-dependent anti-tau antibodies indicated that
tau could be cleaved between the a.a. S409 and S422. Indeed,
truncated tau present in the medium was immunoreactive to the
antibody pS409 but not to the antibody pS422 indicating that
this latter site may be cleaved. Two mutants cleaved at either
S412 (D413–441) or D421 (D422–441), the cleavage site of
caspase-3, were produced and overexpressed in Hela cells [39].
Forty-eight hrs after transfection, the medium was collected and
cells were lysed to analyze the presence of cleaved tau in the
medium and cell lysate by western blotting. Both cleaved tau
mutants were secreted by Hela cells (Figure 6C). Interestingly,
tauD422–441 was significantly more secreted than wild-type tau
whereas tauD413–441 was secreted at levels similar to wild-type
tau. This was well illustrated by the fact that the tauD422–441
mutant was more abundant in the culture medium than in the
cell lysate, a distribution that was never observed with wild-type
tau. To measure the secretion of wild-type tau, tauD413–441
and tauD422–441, the signal of the tau-positive band found at
75 kDa in the medium and the signal of the band correspond-
ing to full-length tau and that at 75 kDa present in the cell
lysate were quantified by densitometry. The secretion of tau was
evaluated by calculating the ratio of the signal obtained with the
anti-tau antibody Tau12 in the culture medium and cell lysate
(Ratio M/L) as described in the previous section. The mean of
the ratio M/L was 0.3760.08, 0.4460.09 and 0.8260.09 for
wild-type tau, tauD413–441 and tauD422–441 respectively
(Figure 6D). For both tauD413–441 and tauD422–441, it
appeared that they were either not cleaved or only cleaved of
few a.a. at the C-terminal during the process of secretion since
the highest tau-positive band presented a similar molecular
weight in both the cell lysate and culture medium. All together,
these results revealed that cleavage of tau at the C-terminal was
a crucial step for its secretion and that the cleavage site was a
determinant factor regulating the amount of tau that was
secreted by Hela cells.
Since tau is preferentially cleaved at D421 by caspase-3, the
activity of caspase-3 was inhibited by Z-DEVD-FMK in Hela cells
overexpressing wild-type tau [39]. The secretion of tau was
evaluated by calculating the ratio of the signal obtained with the
anti-tau antibody Tau12 in the culture medium and cell lysate
(Ratio M/L) as described above. The mean of the ratio M/L
was.6460.076 and.4260.062 for control and treated cells
Figure 5. Secreted tau is dephosphorylated compared to intracellular tau. (A, B, E, F, G, H, I and K) Secreted tau was phosphorylated at
T181, S199, T212, S214, T217, S262, S409 and at the epitope of the AT180 antibody (T231/S235) but to a lesser extent than intracellular tau. (C, D, J
and L) No signal was detected in M with the phospho-tau antibodies directed against phosphorylated S202 (CP13), T205 (pT205), S422 (pS422) and
the S396/S404 (PHF-1) whereas a strong signal was observed in L with these antibodies. Tau12 antibody was used to reveal total tau in M and L. The
pattern of each antibody was analyzed at least in 3 sets of experiments.
doi:10.1371/journal.pone.0036873.g005
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higher than the ratio of cells treated with the caspase-3 inhibitor.
However, the fact that the difference of tau secretion between
control and treated cells was ,20% indicated that only a small
pool of secreted wild-type tau was cleaved by caspase-3. This is
consistent with the fact that wild-type tau was less secreted than
the form of tau truncated at D421.
Discussion
In the present study, we demonstrated that overexpressed
human tau was secreted by Hela cells through an unconventional
secretory pathway. The pool of secreted tau was cleaved at the C-
terminal and was less phosphorylated than intracellular tau. Both
hyperphosphorylation and cleavage at D421 enhanced tau
secretion by Hela cells.
Our results demonstrating that tau was secreted by an
unconventional secretory pathway is consistent with recent studies
reporting that tau was found in exosomes in culture medium from
MC1 cells overexpressing human tau and that secreted tau by
COS-7 and HEK-293 cells was present in microvesicles [11,30]. It
remains to be determined whether tau utilizes other non-
conventional pathways since a portion of tau in the culture
medium of MC1 cells was not associated with exosomes. In the
present study, tau secreted by Hela cells could be immunoprecip-
itated from the culture medium without using any detergent
indicating that it was not included in microvesicles/exosomes.
Consistent with this, no decrease of tau in the medium was
observed after the culture medium was deprived of microvesicles
by ultracentrifugation. All together the above results indicate that
tau is most likely secreted by more than one pathways as shown for
other proteins involved in neurodegenerative diseases such as
Figure 6. Phosphorylation and cleavage at the caspase-3 site enhance tau secretion by Hela cells. (A) Secreted A12 and E12 mutants
were cleaved in M as their migration was faster in M than in L. A12 was secreted in a manner similar to that of wild-type tau whereas E12 was more
secreted than wild-type tau and A12. In both M and L, E12 displayed a decrease in electrophoretic mobility compared to wild-type tau and A12. The
Tau12 antibody was used to reveal tau in L and M. No signal was detected in L prepared from Hela cells transfected with the empty GFP vector (GFP).
(B) Quantification of the secretion ratio M/L of wild-type tau (tau4R), A12 and E12. (C) Two tau mutants cleaved at either S412 (D413–441) or D421
(D422–441), the cleavage site of caspase-3, were secreted by Hela cells. TauD422–441 was significantly more secreted than wild-type tau whereas
tauD413–441 was secreted at similar levels as wild-type tau. No signal was noted with the anti-tau antibody, Tau12, when cells were transfected with
the empty GFP vector (GFP). (D) Quantification of the secretion ratio M/L of wild-type tau (tau4R), tauD413–441 and tauD422–441. The bars represent
the mean of 4 experiments + SEM. p, 0.05.
doi:10.1371/journal.pone.0036873.g006
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protein [40,41,42,43]. In our previous study, we showed that
hyperphosphorylated tau was preferentially associated with the
rough endoplasmic reticulum (RER) membranes in AD brain and
in the tau transgenic mice JNPL3 [44]. An increase of hyperpho-
sphorylated tau was also noted at the Golgi apparatus in the
JNPL3 mice [44]. RER and Golgi have been showed to be
involved in non-conventional secretory pathways [45]. For
example, COPII vesicles budding from the ER and containing
tau at their surface could directly fuse with the plasma membrane
for secretion [45]. This pathway is also used by the signal-peptide-
containing protein, cystic fibrosis transmembrane conductance
regulator (CFTR) [46]. Another possibility is that tau secretion
could occur through non-COPII-coated vesicles forming at the ER
or vesicles forming at the Golgi having tau attached at their surface
[47]. We reported that Tau was found at the surface of RER
membranes but this does not exclude the possibility that it could
end up on the extracellular surface of the plasma membrane
during the fusion process occurring between tau-containing
vesicles and the plasma membrane.
Our results demonstrated that cleavage of tau at D421 increased
its secretion. The fact that wild-type tau and tauD413–441 were
secreted in a similar way by Hela cells strongly suggests that the
major pool of secreted wild-type tau could be cleaved close to S412
in Hela cells. To further demonstrate this, Hela cells overexpress-
ing wild-type tau were treated with a caspase-3 inhibitor since tau
is preferentially cleaved at D421 by this caspase [39]. When Hela
cells were treated with a caspase-3 inhibitor, a small but significant
decrease of wild-type tau secretion was observed. This could
indicate that as mentioned above, the major pool of wild-type tau
secreted by Hela cells was not cleaved at D421. From our results, it
was not possible to conclude whether tauD413–441 and tauD422–
441 underwent further cleavage during the process of secretion.
The fact that they migrated in a similar way in the cell lysate and
Figure 7. A schematic representation of the vicious cycle leading to the amplification of tau secretion in AD. In AD, tau becomes
hyperphosphorylated (1). This hyperphosphorylation would enhance its secretion by either exosomes/microvesicles or another unconventional
secretory pathway (2). Extracellular hyperphosphorylated tau would be dephosphorylated by TNAP present at the plasma membrane (3) and this
would result in an increase of dephosphorylated tau in the extracellular space (4). Dephosphorylated extracellular tau would activate the muscarinic
receptors (5) and this would induce an increase of intracellular calcium (6), an event linked to the increase of tau hyperphosphorylation (7). This
further increase of hyperphosphorylated tau would initiate a vicious circle that would enhance tau secretion.
doi:10.1371/journal.pone.0036873.g007
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by a few amino acids. The secretion of tau cleaved mutants
indicates that wild-type tau was most likely cleaved before its
trafficking in the secretory pathway. Based on a recent study
reporting that an increase of caspase activity is an early event in
AD and our results showing the enhanced secretion of tau cleaved
at the caspase-3 site, one can speculate that the secretion of tau
would be enhanced at the initial stage of the disease [48].
Mimicking of hyperphosphorylation significantly enhanced the
secretion of tau by Hela cells. However, tau found in the culture
medium was dephosphorylated compared to the pool of tau that
remained intracellular. This is consistent with a recent study
reporting that released tau in the culture medium upon cell lysis
was dephosphorylated compared to intracellular tau [26]. In this
study, extracellular tau was not phosphorylated at the epitopes
recognized by the phospho-tau antibodies, AT8 and PHF-1
whereas intracellular tau was. Tissue non-specific alkaline
phosphatases (TNAP) present in the plasma membrane were
shown to be responsible for the dephosphorylation of extracellular
tau [26]. Interestingly, TNAP were shown to be increased in AD
brain [26]. All together, the above data indicate that CSF-tau
might be less phosphorylated than intracellular tau. Several studies
have examined the phosphorylation of tau found in the CSF of
patients affected by a tauopathy. T181 and T231 are the sites that
have been extensively used as a diagnostic tool for AD [8].
Although in most studies, the phosphorylation of T231 was shown
to be increased in AD, some studies reported that its phosphor-
ylation was reduced at later stages of the disease [18]. However,
the phosphorylation of other sites such as the epitopes of AT8 and
PHF-1 remains controversial [8]. Our data revealed that these
epitopes are preferentially dephosphorylated in secreted tau. The
AT8 epitope seems to play a central role in the hyperpho-
sphorylation cascade of tau. Indeed, an increase in phosphoryla-
tion of the AT8 epitope is detected at an early stage of AD
[49,50,51]. In our previous study, we reported that the phosphor-
ylation of the AT8 epitope had the most significant effects on the
phosphorylation of other sites in primary hippocampal neurons
[52]. The results of the present study highlight the possibility that
the dephosphorylation of this epitope could be regulated in a
distinct manner.
In a previous study, it was shown that dephosphorylated tau in
the culture medium could act as an agonist of muscarinic M1 and
M3 receptors inducing a robust and sustained increase of
intracellular calcium that triggered cell death in SH-SY5Y cells
[26]. Most importantly, the increase in intracellular calcium
induced by dephosphorylated tau in the culture medium was
associated with an increase of TNAP expression [26]. Based on
these observations and our present data, one could speculate that
tau found in the extracellular space in AD brain would be
dephosphorylated and thereby would contribute to the aberrant
homeostasis of calcium noted in this tauopathy.
From our data and that of other groups, it appears that both
extracellular and intracellular tau could contribute to the process
of neurodegeneration linked to AD. Furthermore, our data
indicate that in AD, hyperphosphorylation of tau would induce
a vicious circle that would result in the amplification of its
secretion (Figure 7). Indeed, our data revealed that hyperpho-
sphorylation of tau would enhance its secretion and this would in
turn increase the amount of dephosphorylated tau in the
extracellular space. Dephosphorylated extracellular tau would
then induce an increase of intracellular calcium, an event linked to
the increase of tau hyperphosphorylation [26]. This increased
hyperphosphorylation of tau would further enhance its secretion
leading to the emergence of a vicious circle that would promote
the propagation of tau pathology in the brain and its accumulation
in the CSF. The accumulation of total and phospho-tau in the
CSF is used as a diagnostic biomarker for tauopathies [8]. Our
data highlight the possibility that the distinct phosphorylation and
cleavage pattern of tau could account for its differential
accumulation in the CSF among the tauopathies. The character-
ization of this pattern for each tauopathy could become a powerful
tool for their early detection and to distinguish them from one
another.
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